LETTER TO THE EDITOR

ACE-inhibitor/angiotensin receptor blockers (ACE-I/ARBs) therapy in COVID-19 infected dialysis patients

Dear Editor,

The novel severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) enters human cells by binding to the membrane bound angiotensin converting enzyme-2 (ACE-2) [1]. Angiotensin converting enzyme inhibitor/Angiotensin receptor blockers (ACE-I/ARBs) leads to upregulation of ACE-2 expression. This may hypothetically increase the risk of corona virus disease-19 (COVID-19) infection, severity and mortality [1]. Jarcho et al. demonstrated the results of retrospective studies favoring that ACE-I/ARBs therapy is not associated with higher mortality or worse outcomes in COVID-19 patients [2]. Other studies, have shown that the use of ACE-I/ARBs among hospitalized COVID-19 patients is associated with lower mortality [3].

In this meta-analysis, we summarize the results of large multicenter studies that assessed the safety of ACE-I/ARBs therapy in COVID-19 infected end stage renal disease (ESRD) dialysis patients. We involved the large multicenter studies published from the beginning of 2020 till May 2021. Hsu et al. performed a large multicenter study in the USA between February and June 2020. The study included 7948 dialysis patients; out of which 438 experienced COVID-19 infection. About 1/4 of the COVID-19 infected patients died (109/438) [4]. According to the results of Hsu et al., there was no statistically significant association between ACE-I/ARBs therapy and COVID-19 mortality (OR 0.78, 95% CI 0.45–1.33, p = 0.4) [4].

Sanchez-Alvarez et al in their multicenter study included around 580 COVID-19 infected dialysis patients in Spain in March and April 2020 [5]. The mortality rate was 26.3%. On multivariate analysis, ARBs therapy was also not associated with higher COVID-19 mortality (OR 0.66, 95% CI 0.38–1.12, p = 0.12) [5].

Lano et al conducted a multicenter observational cohort study in France between March and May 2020 [6]. A total of 2336 dialysis patients were enrolled. Out of 129 COVID-19 infected patients 34 died. Interestingly, this study showed a protective effect of ARBs therapy on mortality in COVID-19 infected dialysis patients (OR 0.093, 95% CI 0.005–0.54, p = 0.03). However, the authors outlined the limitation of the observational retrospective design of the study [6]. On pooling the data from the 3 aforementioned studies together, we found that ACE-I/ARBs therapy is associated with a protective effect among COVID-19 infected dialysis patients (OR 0.49, 95% CI 0.03–0.94, p = 0.007). These findings are demonstrated in Figure 1. A possible interpretation of our results is that patients not on ACE-I/ARBs might have a baseline hypotension with other multiple risk factors including frailty, all attributing to increased mortality. This may be confounded in favor of the use of ACE-I/ARBs in the hypertensive ESRD cohort. A clue to support this hypothesis, is the “apparent” protective effect of hypertension on mortality in COVID-19 infected dialysis patients found by Hsu et al. (OR 0.50, 95% CI 0.29–0.87, p = 0.01).

Figure 1. Relationship between ACE-I/ARBs therapy and mortality in COVID-19 infected dialysis patients.
CI 0.26–0.96, \( p = 0.04 \) [3] and by the ERA CODA study (OR 0.61, 95\% CI 0.42–0.88, \( p < 0.001 \)) [7].

**Conclusion**

Our results are in favor of the safe use of ACE-I/ARBs in COVID-19 infected ESRD dialysis patients. A possible protective effect is yet to be determined by further randomized controlled trials assessing the effect of ACE-I/ARBs therapy in COVID-19 infected dialysis patients. It is hard to reach solid conclusions from our meta-analysis due to the small number of studies included due to paucity of literature available.

**Disclosure statement**

No potential conflict of interest was reported by the author(s). Drs. Rao and Soliman are members of the editorial board of Renal Failure.

**Funding**

The author(s) reported there is no funding associated with the work featured in this article.

**References**

[1] Bian J, Li Z. Angiotensin-converting enzyme 2 (ACE2): SARS-CoV-2 receptor and RAS modulator. Acta Pharm Sin B. 2021;11(1):1–12.

[2] Jarcho JA, Ingelfinger JR, Hamel MB, et al. Inhibitors of the renin-angiotensin-aldosterone system and covid-19. N Engl J Med. 2020;382(25):2462–2464.

[3] Zhang P, Zhu L, Cai J, et al. Association of inpatient use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19. Circ Res. 2020;126(12):1671–1681.

[4] Hsu CM, Weiner DE, Aweh G, et al. COVID-19 among US dialysis patients: risk factors and outcomes from a national dialysis provider. Am J Kidney Dis. 2021;77(5):748–756.e1.

[5] Sánchez-Alvarez E, Macía M, de Sequera Ortiz P. Management of hemodialysis patients with suspected or confirmed COVID-19 infection: perspective from the Spanish nephrology. Kidney360. 2020;1(11):1254–1258.

[6] Lano G, Braconnier A, Bataille S, et al. Risk factors for severity of COVID-19 in chronic dialysis patients from a multicentre french cohort. Clin Kidney J. 2020;13(5):878–888.

[7] Hilbrands LB, Duivenvoorden R, Vart P, ERACODA Collaborators, et al. COVID-19-related mortality in kidney transplant and dialysis patients: results of the ERACODA collaboration. Nephrol Dial Transplant. 2020;35(11):1973–1983.